Federated Hermes
CTKB icon

Federated Hermes’s Cytek Biosciences CTKB Stock Holding History

Federated Hermes’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.3K Buy
5,335
+756
+17% +$3.57K ﹤0.01% 1760
2025
Q4 		$23.1K Buy
4,579
+231
+5% +$1.07K ﹤0.01% 1743
2025
Q3 		$15.1K Sell
4,348
-2,873
-40% -$10.8K ﹤0.01% 1838
2025
Q2 		$24.6K Buy
7,221
+4,343
+151% +$14.5K ﹤0.01% 1693
2025
Q1 		$11.5K Sell
2,878
-4,770
-62% -$24.7K ﹤0.01% 1790
2024
Q4 		$49.6K Buy
7,648
+624
+9% +$3.72K ﹤0.01% 1666
2024
Q3 		$38.9K Buy
7,024
+2,991
+74% +$17K ﹤0.01% 1691
2024
Q2 		$22.5K Sell
4,033
-154
-4% -$925 ﹤0.01% 1707
2024
Q1 		$28.1K Buy
4,187
+191
+5% +$1.51K ﹤0.01% 1689
2023
Q4 		$36.4K Buy
+3,996
New +$25.1K ﹤0.01% 1687

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Federated Hermes's CTKB Position: Q1 2026 in Review

Federated Hermes increased its Cytek Biosciences (CTKB) stake by 17% in Q1 2026, buying an estimated $3.57K and bringing the position to 5,335 shares worth $23.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1760.

Federated Hermes first reported a position in CTKB in Q4 2023 and has held it in 10 quarters since. The position peaked at $49.6K in Q4 2024. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Federated Hermes held 5,335 shares of Cytek Biosciences worth $23.3K as of Q1 2026.
  • Federated Hermes bought 756 Cytek Biosciences shares in Q1 2026, an estimated $3.57K.
  • Cytek Biosciences made up ﹤0.01% of Federated Hermes's portfolio in Q1 2026, its #1760 holding.
  • Federated Hermes first reported a position in Cytek Biosciences in Q4 2023 and has held it in 10 quarters since.
  • Federated Hermes's Cytek Biosciences position peaked at $49.6K in Q4 2024.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.